Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00405938 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer
A Phase 2 study of Breast Cancer and Breast Neoplasms, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
- 11
- Study locations
NCT00405938: Completed Phase 2 study of Breast Cancer and Breast Neoplasms, sponsored by SCRI Development Innovations.
NCT00405938 is a Phase 2 study of Breast Cancer and Breast Neoplasms that has completed, run by SCRI Development Innovations. The registered enrollment target is 79 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 11 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00405938, a Phase 2 study of Breast Cancer and Breast Neoplasms, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a phase II trial combining bevacizumab with either fulvestrant or anastrozole with trastuzumab in the treatment of metastatic breast cancer in postmenopausal women. It is hoped that these combinations will keep the cancer from growing and spreading further.
Primary Outcome
Progression Free Survival (PFS) is defined as the interval, in months, from the date of first treatment to the date of disease progression or death, whichever occurred first.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Anastrozole
- DRUG Fulvestrant
Study Locations (11)
Florida
- Florida Cancer Specialists - Fort Myers
- Integrated Community Oncology Network - Jacksonville
- Florida Hospital Cancer Institute - Orlando
Georgia
- Northeast Georgia Medical Center - Gainesville
- Wellstar Cancer Research - Marietta
Tennessee
- Chattanooga Oncology & Hematology Associates - Chattanooga
- Tennessee Oncology, PLLC - Nashville
Kentucky
- Graves-Gilbert Clinic - Bowling Green
Louisiana
- Baton Rouge General Medical Center - Baton Rouge
Missouri
- St. Louis Cancer Care - Chesterfield
Montana
- Sletten Cancer Institute - Great Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2006-11 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
What the finished NCT00405938 record still lists
NCT00405938 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00405938 lists 11 locations in 7 states (Florida, Georgia, Tennessee).
Frequently Asked Questions
What is clinical trial NCT00405938 about?
NCT00405938 is a clinical study titled "Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer". This is a phase II trial combining bevacizumab with either fulvestrant or anastrozole with trastuzumab in the treatment of metastatic breast cancer in postmenopausal women. It is hoped that these combinations will keep the cancer from growing and spreading further.
What is the current status of trial NCT00405938?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2006-11. Estimated completion is 2011-06.
What conditions does trial NCT00405938 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Neoplasms.
What interventions are being tested in trial NCT00405938?
The interventions under investigation include: Bevacizumab (DRUG), Anastrozole (DRUG), Fulvestrant (DRUG).
Who is sponsoring clinical trial NCT00405938?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00405938 being conducted?
This trial has 11 study locations across Florida, Georgia, Kentucky, Louisiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00405938's enrollment target sits among peer trials
79 660th of 1224 higher than 564 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia